LAMIVUDINE AND ZIDOVUDINE

N/A

Manufactured by ViiV Healthcare Company

16,773 FDA adverse event reports analyzed

Last updated: 2026-04-14

About LAMIVUDINE AND ZIDOVUDINE

LAMIVUDINE AND ZIDOVUDINE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by ViiV Healthcare Company. The most commonly reported adverse reactions for LAMIVUDINE AND ZIDOVUDINE include DRUG EXPOSURE DURING PREGNANCY, FOETAL EXPOSURE DURING PREGNANCY, PAIN, ANXIETY, EMOTIONAL DISTRESS. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for LAMIVUDINE AND ZIDOVUDINE.

Top Adverse Reactions

DRUG EXPOSURE DURING PREGNANCY1,149 reports
FOETAL EXPOSURE DURING PREGNANCY710 reports
PAIN600 reports
ANXIETY565 reports
EMOTIONAL DISTRESS555 reports
ANHEDONIA502 reports
ANAEMIA453 reports
ABORTION SPONTANEOUS443 reports
MATERNAL EXPOSURE DURING PREGNANCY379 reports
PREMATURE BABY362 reports
CHRONIC KIDNEY DISEASE326 reports
PYREXIA283 reports
STILLBIRTH277 reports
NAUSEA269 reports
OSTEOPOROSIS268 reports
DEPRESSION267 reports
RENAL FAILURE267 reports
FATIGUE263 reports
EXPOSURE DURING PREGNANCY256 reports
DIARRHOEA245 reports
VOMITING232 reports
ASTHENIA197 reports
PREGNANCY196 reports
BONE DENSITY DECREASED193 reports
ECONOMIC PROBLEM190 reports
ABORTION INDUCED188 reports
RENAL IMPAIRMENT180 reports
OSTEOPENIA178 reports
CAESAREAN SECTION169 reports
HEADACHE168 reports
DYSPNOEA155 reports
RASH151 reports
NEUTROPENIA145 reports
GAIT DISTURBANCE140 reports
DRUG INTERACTION138 reports
ACUTE KIDNEY INJURY136 reports
ALANINE AMINOTRANSFERASE INCREASED136 reports
ARTHRALGIA127 reports
BLOOD CREATININE INCREASED126 reports
DRUG INEFFECTIVE121 reports
LIVE BIRTH121 reports
DIZZINESS120 reports
LIPODYSTROPHY ACQUIRED120 reports
WEIGHT DECREASED118 reports
ASPARTATE AMINOTRANSFERASE INCREASED117 reports
ABDOMINAL PAIN115 reports
VIROLOGIC FAILURE111 reports
DEATH105 reports
INSOMNIA104 reports
HEPATITIS103 reports
HYPERTENSION102 reports
HAEMOGLOBIN DECREASED101 reports
MALAISE101 reports
PANCYTOPENIA101 reports
END STAGE RENAL DISEASE100 reports
PATHOGEN RESISTANCE99 reports
VIRAL MUTATION IDENTIFIED98 reports
MATERNAL DRUGS AFFECTING FOETUS97 reports
LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES96 reports
BONE DEMINERALISATION95 reports
ABDOMINAL DISTENSION94 reports
PNEUMONIA94 reports
BACK PAIN93 reports
OSTEONECROSIS92 reports
PAIN IN EXTREMITY87 reports
TREATMENT NONCOMPLIANCE86 reports
COUGH85 reports
PREMATURE DELIVERY84 reports
PRURITUS84 reports
DRUG RESISTANCE81 reports
JAUNDICE80 reports
PREMATURE LABOUR80 reports
THROMBOCYTOPENIA80 reports
LEUKOPENIA75 reports
POLYDACTYLY75 reports
SEPSIS75 reports
BLOOD CREATINE PHOSPHOKINASE INCREASED73 reports
CARDIAC MURMUR73 reports
TRISOMY 2172 reports
INTRA UTERINE DEATH71 reports
MULTIPLE FRACTURES71 reports
BLOOD BILIRUBIN INCREASED70 reports
GASTROINTESTINAL DISORDER70 reports
NEPHROLITHIASIS70 reports
PRE ECLAMPSIA69 reports
VENTRICULAR SEPTAL DEFECT68 reports
GENERAL PHYSICAL HEALTH DETERIORATION67 reports
PREMATURE RUPTURE OF MEMBRANES67 reports
CONGENITAL ANOMALY66 reports
ATRIAL SEPTAL DEFECT65 reports
HEPATOTOXICITY65 reports
MYALGIA64 reports
NORMAL NEWBORN64 reports
MOBILITY DECREASED63 reports
OEDEMA PERIPHERAL63 reports
CONFUSIONAL STATE62 reports
CONGENITAL CENTRAL NERVOUS SYSTEM ANOMALY62 reports
NEUROPATHY PERIPHERAL62 reports
DIABETES MELLITUS61 reports
LOW BIRTH WEIGHT BABY61 reports

Report Outcomes

Out of 7,687 classified reports for LAMIVUDINE AND ZIDOVUDINE:

Serious 89.8%Non-Serious 10.2%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female3,600 (51.8%)
Male3,286 (47.3%)
Unknown58 (0.8%)

Reports by Age

Age 0202 reports
Age 33165 reports
Age 36152 reports
Age 35151 reports
Age 30137 reports
Age 32137 reports
Age 39136 reports
Age 27134 reports
Age 40134 reports
Age 31133 reports
Age 29124 reports
Age 38122 reports
Age 25120 reports
Age 34118 reports
Age 37117 reports
Age 1116 reports
Age 28114 reports
Age 44113 reports
Age 4299 reports
Age 4998 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with LAMIVUDINE AND ZIDOVUDINE?

This profile reflects 16,773 FDA FAERS reports that mention LAMIVUDINE AND ZIDOVUDINE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for LAMIVUDINE AND ZIDOVUDINE?

Frequently reported terms in FAERS include DRUG EXPOSURE DURING PREGNANCY, FOETAL EXPOSURE DURING PREGNANCY, PAIN, ANXIETY, EMOTIONAL DISTRESS, ANHEDONIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures LAMIVUDINE AND ZIDOVUDINE?

Labeling and FAERS entries often list ViiV Healthcare Company in connection with LAMIVUDINE AND ZIDOVUDINE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.